Cladribine and medium-dose cytarabine intensified busulfan plus cyclophosphamide conditioning regimen for adults high-risk B-cell acute lymphoblastic leukemia
Annals of Hematology · 2025
DOI: 10.1007/s00277-025-06471-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Hematology, 2025. Verfasst von Tingting Cheng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Xiangya Hospital, Central South University, Changsha, China. Hauptthemen laut MEDLINE: Transplantation Conditioning, Antineoplastic Combined Chemotherapy Protocols, Hematopoietic Stem Cell Transplantation, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the most effective salvage strategy for B-cell acute lymphoblastic leukemia (B-ALL). In this study, we explored the efficacy and safety of cladribine and medium-dose cytarabine intensified busulfan plus cyclophosphamide conditioning regimen (CBAC) for high-risk B-ALL patients at complete remission (CR) after chemotherapy undergoing allo-HSCT. And compared it with patients historical received traditional total body irradiation plus cyclophosphamide (TBI-Cy) regimen. The 3-year non-relapse mortality (NRM), cumulative incidence of relapse (CIR), disease-free survival (DFS) and overall survival (OS) of CBAC and TBI-Cy group were 15.0% vs. 11.1% (p = 0.576), 17.3% vs. 35.7% (p = 0.077), 67.7% vs. 53.2% (p = 0.235) and 74.3% vs. 66.8% (p = 0.482). Overall cohort multivariate analysis indicated TBI-Cy increased the risk of relapse after transplantation compared with CBAC (HR: 2.544, p = 0.049). Subgroup analysis revealed that among cytogenetic high-risk patients, the CBAC group showed a trend of higher 3-year DFS (75.1% vs 52.6%, p = 0.073). Among patients with minimal residual disease positive (MRD+) at transplantation, the CBAC group showed higher 3-year DFS (60.0% vs 11.1%, p = 0.018). In conclusion, CBAC conditioning regimen may reduce relapse without increasing NRM, improving the prognosis of high-risk B-ALL patients, especially those with cytogenetic high-risk factors or MRD+ at transplantation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Xiangya Hospital, Central South University, Changsha, China.
- National Clinical Research Center for Geriatric Diseases (Xiangya Hospital), Changsha, China.
- Hunan Hematology Oncology Clinical Medical Research Center, Changsha, China.
- Department of Hematology, Xiangya Hospital, Central South University, Changsha, China. yanchen2018@csu.edu.cn.
- National Clinical Research Center for Geriatric Diseases (Xiangya Hospital), Changsha, China. yanchen2018@csu.edu.cn.
- Hunan Hematology Oncology Clinical Medical Research Center, Changsha, China. yanchen2018@csu.edu.cn.
Zitieren
APA
Cheng, T., Peng, J., Liu, Y., Yang, S., Chen, Y., & Xu, Y. (2025). Cladribine and medium-dose cytarabine intensified busulfan plus cyclophosphamide conditioning regimen for adults high-risk B-cell acute lymphoblastic leukemia. Annals of Hematology. https://doi.org/10.1007/s00277-025-06471-2
Vancouver
Cheng T, Peng J, Liu Y, Yang S, Chen Y, Xu Y. Cladribine and medium-dose cytarabine intensified busulfan plus cyclophosphamide conditioning regimen for adults high-risk B-cell acute lymphoblastic leukemia. Annals of Hematology. 2025. doi:10.1007/s00277-025-06471-2
BibTeX
@article{Cheng2025,
author = {Cheng, Tingting and Peng, Jie and Liu, Yi and Yang, Shuanghui and Chen, Yan and Xu, Yajing},
title = {Cladribine and medium-dose cytarabine intensified busulfan plus cyclophosphamide conditioning regimen for adults high-risk B-cell acute lymphoblastic leukemia},
journal = {Annals of Hematology},
year = {2025},
doi = {10.1007/s00277-025-06471-2}
}
EUVIMED